Scilex announces the continuing support from Endeavor Distribution

Scilex announced the continuing support from Endeavor Distribution on Scilex’s commercial products and the satisfaction of the FSF 33433 LLC $10 million loan under the Commitment Side Letter dated June 11, 2024. “I am very excited that this agreement with one of the premier healthcare and distribution services providers in the U.S. will expand access to ZTlido, ELYXYB, and GLOPERBA for thousands of patients suffering from acute and chronic pain. This partnership strengthens the progress we’ve achieved with key customers and point of care facilities over the past few months,” says Scilex’s Chief Executive Officer, Jaisim Shah, “Scilex remains committed to our goal of ensuring broad access to ZTlido and our other important non-opioid products.”